Table 1 Main demographic and clinical parameters of the patients who developed (25; group A) and did not develop (183; group B) TCD4pos lymphocytosis at baseline
From: TCD4pos lymphocytosis in rheumatoid and psoriatic arthritis patients following TNFα blocking agents
N. pts | Age (years) | M/F | RA/PsA | DAS28 | Disease duration (years) | Biological N (%) | ccs use (%) | Lymphocyte count (cells/μl) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Etn | Ada | Ifx | Gol | Cert | ||||||||
25 | 58 ± 13 | 9/16 | 15/10 | 6.2 | 4.2 ± 5.6* | 11 (44) | 7 (28) | 4 (16) | 3 (12) | 0 | 60^ | 2800 ± 499✝ |
183 | 59.6 ± 14 | 59/124 | 116/67 | 5.6 | 8.2 ± 6.9 | 98 (54) | 53 (29) | 15 (8) | 12 (6) | 5 (3) | 40 | 1866 ± 362 |